The IMA Group Marks 35 Years of Growth from Medical Evaluations to National Clinical Research Network

The IMA Group (IMA) marks its 35th anniversary this year, reflecting both resilience and reinvention under the leadership of President and CEO Mark Weinberger. Over the past 14 years, Weinberger and his team have transformed the company from its origins in medical screenings and psychological evaluations into a national organization with more than 150 locations and a rapidly expanding clinical research network. A licensed psychologist and psychiatric epidemiologist, Weinberger combines scientific insight with business strategy, driven by the conviction that better data and clearer access to services enable better decisions for patients, clients, and communities.

IMA's longevity rests on three pillars: great people, commitment to quality, and willingness to adapt and evolve. Founded by industry pioneer David Pulver, MD, in 1990, the company has built a culture centered on purpose, adaptability, and accountability. Weinberger emphasizes that striking the right balance between agility and consistency—always anchored in quality—has kept the organization relevant and trusted for decades. The company invests in scalable systems and exceptional talent to evolve alongside shifting policies, payer expectations, and care models.

Today, IMA operates as a national leader in outsourced medical, psychological, and ancillary evaluations and screenings, serving government agencies, insurers, third-party administrators, and employers. For public safety programs, they deliver psychological and medical assessments needed to evaluate police officers, firefighters, and other essential personnel. For workers' compensation, disability, injury, or auto liability claims, they support insurers and employers through independent medical exams, medical file reviews, case management, and rehabilitation guidance. The common thread connecting these diverse audiences is a shared need for objective, high-fidelity clinical insights delivered at scale.

The company's expansion into clinical research represents a natural evolution from its evaluation foundation. In 2018, IMA formalized a growth strategy combining organic investment with targeted acquisitions—ultimately acquiring 19 businesses, 10 of which now form part of their research division. This strategic move created IMA Clinical Research, leveraging the company's existing clinic footprint, technology, and clinical expertise to connect patients to new treatment opportunities. The research network now includes 19 dedicated sites conducting Phase II-IV clinical trials, located in communities ranging from New York and Chicago to Albuquerque, New Mexico, and Hickory, North Carolina.

IMA's national clinic network provides significant benefits for both patients and research sponsors. For sponsors, the combined footprint creates infrastructure capable of recruiting diverse, representative patient populations more quickly while delivering high-quality data. For patients, it means access to clinical research opportunities and evaluation services in their local communities without extensive travel. The company has further expanded reach through satellite and outreach sites, recognizing that local accessibility builds trust and engagement essential for both accurate evaluations and successful clinical trials.

Technology plays a crucial role in IMA's patient-centric approach. Across the enterprise, the organization uses AI tools and predictive modeling to optimize trial recruitment, match patients efficiently, and analyze data with greater precision. They support telehealth visits, mobile data capture, remote monitoring, and home visits—all designed to reduce barriers and improve convenience. For evaluations, secure scheduling dashboards, portals, and real-time tracking ensure transparency and timely reporting. The goal is to use technology to make processes seamless so providers and study coordinators can focus on quality, accuracy, and meaningful patient engagement.

Looking ahead, IMA sees tremendous growth potential across both evaluation and research platforms. In clinical research, the focus includes therapeutic areas like central nervous system disorders, sleep, and metabolic disease, where clinical gaps remain significant, as well as GLP-1 studies that continue to expand rapidly. The company is committed to improving representation in clinical trials, ensuring generated data reflects the populations treatments are designed to serve. Beyond therapeutic areas, IMA is scaling workers' compensation, liability, auto/no-fault, and occupational health evaluations in response to evolving regulations and workforce needs. They're also piloting new models in hybrid and decentralized trials, advanced biomarkers, and real-world evidence integration.

Throughout its evolution, IMA remains guided by a unifying principle: quality, clinical excellence, scientific rigor, and compassionate humanity. These principles have sustained the organization for 35 years and continue to focus its mission on advancing health, supporting people, and earning trust every day. The company's journey from medical evaluations to integrated clinical research demonstrates how foundational clinical expertise can drive sustainable expansion while maintaining core values.